eISSN 2234-3814

Table. 1.

Table. 1.

Ongoing clinical trials using liquid biopsy for somatic mutation detection in gastric cancer

Study No. Study type Status Start date Conditions Primary outcome measure
NCT06036563 O N/R Sep 2023 Common cancers Diagnostic accuracy of cfDNA for screening and differentiating common cancers, including gastric cancer, in participants compared with a reference histological test
NCT06028724 O R May 2023 Solid tumors Prevalence of clinically useful mutations in solid tumors, including gastric cancer by a next-generation sequencing-based cfDNA method
NCT05366881 O R May 2022 Multiple types of cancer Differentiation between cancer and non-cancer signals from patients and controls based on cfDNA analysis using a genome-wide methylome enrichment platform
NCT05227261 O R Apr 2022 Common cancers of the lung, breast, liver, colorectum, and stomach Positive/negative predictive values of blood cfDNA in early cancer detection
NCT05347524 O R Mar 2022 Gastric cancer with peritoneal metastasis Sensitivity and specificity of cfDNA methylation-based assay for detecting peritoneal metastasis of gastric cancer
NCT05513144 O R Dec 2021 Advanced ERBB2-negative gastric cancer Molecular changes over the course of disease progression may serve as a prognostic marker for diagnosis and treatment response
NCT05027347 O R Oct 2021 Early-stage gastric cancer Sensitivity and specificity of a cfDNA assay for detecting early-stage gastric cancer
NCT05029869 O R Oct 2021 Gastric cancer after gastrectomy Sensitivity of a cfDNA assay for monitoring minimal residual disease
NCT05059444 O R Sep 2021 Early-stage solid tumors treated Detection of distant recurrence-free intervals in individuals treated for early-stage solid tumors
NCT05224596 O R Jan 2021 Gastric cancer Sensitivity and specificity of a cfDNA methylation-based assay for detecting gastric cancer
NCT04253106 I R Nov 2020 Hereditary diffuse gastric cancer Percentage of patients with somatic mutations or methylation profiles using liquid biopsy
NCT04484636 I R Oct 2020 Gastrointestinal cancer Measurement of genomic profiles
NCT04943406 O R May 2020 Locally advanced gastric cancer Overall and disease-free survival based on ctDNA positivity in peritoneal lavage and peripheral blood of patients with locally advanced gastric cancer
NCT03957564 I R May 2019 Gastric cancer, gastro-esophageal junction cancer Detection of circulating tumor cells and cfDNA before and after neoadjuvant chemotherapy and surgery

The information of clinical trials was obtained from (accessed on October 2, 2023).

Abbreviations: O, observational; I, interventional; R, recruiting; N/R, not yet recruiting; cfDNA, cell-free DNA.

Ann Lab Med 2024;44:119~121

© Ann Lab Med